期刊
CELL CYCLE
卷 14, 期 13, 页码 2100-2108出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15384101.2015.1041693
关键词
cisplatin; chemosensitization; DNA repair; osteosarcoma; protein phosphatase 2A
类别
资金
- National Natural Science Foundation Program [NSFC81102042]
- Xinqiao Hospital, Third Military Medical University (Chongqing, China)
- National Institute of Neurological Disorders and Stroke at the National Institutes of Health (Bethesda, MD, USA)
Osteosarcoma is the most common primary malignant bone tumor and affects a significant portion of pediatric oncology patients. Although surgery and adjuvant chemotherapy confer significant survival benefits, many patients go on to develop metastatic disease, particularly to the lungs, secondary to development of drug resistance. Inhibition of protein phosphatase 2A with the small molecule, LB100, has demonstrated potent chemo- and radio-sensitizing properties in numerous pre-clinical tumor models. In this study, we showed that LB100 overcame DNA repair mechanisms in osteosarcoma cells treated with cisplatin, in vitro, and recapitulated these findings in an in vivo xenograft model. Notably, the addition of LB100 to cisplatin prevented development of pulmonary metastases in the majority of treated animals. Our data indicated the mechanism of chemo-sensitization by LB100 involved abrogation of the ATM/ATR-activated DNA damage response, leading to hyperphosphorylation of Chk proteins and persistent cyclin activity. In addition, LB100 exposure suppressed Akt signaling, leading to Mdm2-mediated proteasomal degradation of functional p53. Taken together, LB100 prevented repair of cisplatin-induced DNA damage, resulting in mitotic catastrophe and cell death.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据